Drugs / FGFR4-CAR T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06865664 | Sep 2025 → Dec 2027 expected | rhabdomyosarcoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FGFR4-CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06865664 ↗ |
| Action | Deplete | “better able to target the FGFR4 protein and attack RMS tumor cells.” NCT06865664 ↗ |
| Modality | Cell therapy | “The modified T cells are chimeric antigen receptor (CAR) T cells.” NCT06865664 ↗ |
| Route | Intravenous | “the modified T cells will be infused into a vein” NCT06865664 ↗ |
| Target | FGFR4 | “better able to target the FGFR4 protein and attack RMS tumor cells.” NCT06865664 ↗ |